Tech Center 1700 • Art Units: 1631 1633 1799
This examiner grants 38% of resolved cases
Quang Nguyen is an examiner in Tech Center 1700 and Art Unit 1631. His record includes 749 resolved cases, which provides a basis for understanding his prosecution patterns. The allowance rate for these cases is 38.1%. This 38.1% rate indicates the frequency with which applications reach a grant under his review. Practitioners can use this figure to assess the challenging prosecution environment in Art Unit 1631.
The median days to allowance is 1480. This 1480-day figure represents the middle point of the timeline for applications that result in a patent grant. It serves as a practical benchmark for managing expectations regarding the duration of the examination process. The 1480-day median is a key metric for applicants to consider when planning their patent strategy and budgeting for prosecution costs in Tech Center 1700.
The data also shows an interview lift of 52.7%. This 52.7% lift represents the increase in the allowance rate associated with conducting an examiner interview. Practitioners should evaluate this 52.7% lift as a primary strategy for advancing prosecution. While the base allowance rate is 38.1%, the 52.7% lift suggests that direct communication is a highly effective tool for resolving outstanding issues and securing a grant. This lift provides a measurable basis for deciding whether to engage in an interview.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18314773 | USE OF AAV-EXPRESSED M013 PROTEIN AS AN ANTI-INFLAMMATORY THERAPEUTIC | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18191790 | AAV-BASED GENE THERAPY FOR MULTIPLE SCLEROSIS | Final Rejection | University of Florida Research Foundation, Incorporated. |
| 18558919 | COMPOSITIONS AND METHODS RELATED TO THE TREATMENT OF OCULAR DISEASES IN EQUINES | Final Rejection | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL |
| 18334530 | METHODS AND COMPOSITIONS FOR CIRCULAR RNA MOLECULES | Final Rejection | The University of North Carolina at Chapel Hill |
| 16761876 | METHODS AND COMPOSITIONS FOR CIRCULAR RNA MOLECULES | Non-Final OA | The University of North Carolina at Chapel Hill |
| 17999762 | COMPOSITIONS AND METHODS FOR EPIGENOME EDITING | Final Rejection | The Regents of the University of California |
| 17932026 | METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE | Final Rejection | CureVac Manufacturing GmbH |
| 15750745 | METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE | Final Rejection | CureVac Manufacturing GmbH |
| 16535042 | INDUCIBLE DNA BINDING PROTEINS AND GENOME PERTURBATION TOOLS AND APPLICATIONS THEREOF | Non-Final OA | Massachusetts Institute of Technology |
| 17272194 | GENE THERAPY FOR THE TREATMENT OF GALACTOSEMIA | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18559667 | PRODUCTION OF THERAPEUTIC MESENCHYMAL STEM CELL-DERIVED EXOSOMES | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17973773 | VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | Final Rejection | Novartis AG |
| 18282139 | TARGETED INSERTION VIA TRANSPOSITION | Non-Final OA | The Curators of the University of Missouri |
| 17178972 | GENERATING GABAergic NEURONS IN BRAINS | Non-Final OA | The Penn State Research Foundation |
| 18517080 | COMPOSITIONS AND METHODS OF TREATING USHER SYNDROME III | Final Rejection | CASE WESTERN RESERVE UNIVERSITY |
| 18286847 | HSV AMPLICON PACKAGING SYSTEM USING ENGINEERED CELLS | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18173485 | METHODS FOR ENHANCING ANTI-TUMOR ACTIVITY OF EXHAUSTED T CELLS | Final Rejection | FRED HUTCHINSON CANCER CENTER |
| 17260418 | LIPID PARTICLE CONTAINING A-TYPE CpG OLIGODEOXYNUCLEOTIDE | Non-Final OA | TEIKYO UNIVERSITY |
| 18563175 | CRISPR-CAS3 SYSTEMS FOR TARGETED GENOME ENGINEERING | Non-Final OA | CORNELL UNIVERSITY |
| 17773416 | Recombinant CDKL5 Proteins, Gene Therapy and Production Methods | Non-Final OA | Amicus Therapeutics, Inc. |
| 18156184 | Oncolytic Vaccinia Virus | Final Rejection | Queen Mary University of London |
| 18194383 | GENETICALLY MODIFIED MESENCHYMAL STEM CELLS EXPRESSING ALPHA-1 ANTITRYPSIN (AAT) | Non-Final OA | JunctuCell Biomed Manufacturing GmbH |
| 16933773 | NUCLEIC ACID PURIFICATION | Final Rejection | ZYMO RESEARCH CORPORATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy